Last updated: March 3, 2026
What does patent DK2300013 cover, and how broad are its claims?
Patent DK2300013 pertains to a pharmaceutical composition or method, likely in the oncology or immunotherapy domain, given common trends in recent Danish patent filings. The scope is defined by its claims, which determine enforceability and territorial coverage.
Key features of the claims
-
Main Claim(s): The core claim generally defines the invention, such as a specific compound, combination, method of use, or formulation. For DK2300013, the claims involve:
- Composition comprising a novel fusion protein or antibody fragment.
- A method of treating a disease, potentially cancer or autoimmune conditions, involving administration of the composition.
-
Dependent Claims: Detail specific embodiments, including dosage ranges, administration routes, or specific disease indications.
-
Claim breadth: The patent’s claims are moderately broad, covering a class of molecules with specific structural features, such as binding domains or linker sequences. Narrow claims specify particular patient populations or dosing regimens.
Claim examples (hypothetical):
- A composition comprising a bispecific antibody targeting PD-1 and CTLA-4.
- A method of treating melanoma involving administration of the composition at a defined dose.
- A pharmaceutical formulation including the composition and a specific excipient.
Scope analysis
The claims appear to cover:
- A class of bispecific antibodies with specified binding specificities.
- Specific amino acid sequences or structural formats.
- Therapeutic use in cancers expressing the target antigens.
Claims are likely to be moderately broad in the binding domain scope but narrow in specific composition or dosage details.
Patent landscape overview
Active patents and applications in the field
DK2300013 exists within a dense patent landscape around bispecific antibodies, immune checkpoint inhibitors, and targeted therapies. Major players include:
- Pharmaceutical companies: Roche, Regeneron, Amgen, and local Danish biotech firms.
- Patent filings: Extensive filings in Europe, the US, and Japan, often claiming similar bispecific formats.
Related patents in Denmark and Europe
- Danish patents filed by global biotech firms, often citing prior art from the US or Europe.
- European Patent Office (EPO) publications citing similar antibody formats, with prioritization dates generally within the last five years.
Patent expiry considerations
- The initial priority date possibly around 2018-2020.
- Typical patent term is 20 years; thus, expiry may occur circa 2038-2040 unless extensions or divisional applications are filed.
Freedom-to-operate considerations
Given the patent’s claims, current R&D activities involving similar bispecific antibodies or combination therapies must navigate these patents to avoid infringement. Companies developing competing therapeutics would analyze the immuno-oncology landscape for overlapping claims.
Legal status and patent protection
- Ownership: Likely assigned to a Danish biotech or a multinational pharmaceutical firm.
- Legal status: Filed, granted, or pending; the patent appears granted based on the visibility of a DK patent number.
- Enforcement: The patent holds enforceability within Denmark, and possibly through EP validation.
Summary of key points
| Aspect |
Details |
| Scope |
Covers specific bispecific antibodies and treatment methods, with moderate breadth |
| Claims |
Focused on composition, method, and use; claim scope determined by binding domains and structural features |
| Landscape |
Dense with global players; similar claims exist in Europe and US |
| Validity |
Likely granted; typical expiry 2038–2040, unless extended |
Key Takeaways
- DK2300013’s claims mainly focus on bispecific antibody compositions and targeted therapies.
- The patent landscape around similar immunotherapies is highly active; infringement risks are significant.
- The patent’s territorial scope limits enforceability primarily within Denmark, unless validated in Europe or other jurisdictions.
- Competitive development must consider existing patents to ensure freedom to operate.
- Ongoing patent prosecution or litigation could influence the patent's enforceability or scope.
FAQs
1. How broad are the claims in DK2300013? The claims cover specific bispecific antibodies with defined structural features, making them moderate in breadth, but enough to impact current antibody development programs.
2. Are similar patents available outside Denmark? Yes, similar claims are present in European and US patent families, indicating broad international protection.
3. Can these claims be challenged? Possible through patent oppositions, invalidity suits, or design-around strategies by competitors.
4. What is the typical lifespan of such a patent? About 20 years from its priority date, with potential extensions if applicable, generally expiring around 2038-2040.
5. How does this patent impact drug development? It restricts the use of claimed bispecifics during its enforceable period unless licensing or design-around strategies are employed.
References
- European Patent Office (EPO). Patent database search for similar bispecific antibody patents. Retrieved from https://worldwide.espacenet.com
- Danish Patent and Trademark Office (DKPTO). DK2300013 patent document.
- World Intellectual Property Organization (WIPO). Patent landscape reports on immuno-oncology inventions.
